ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
FOXR2 Stabilizes MYCN Protein and Identifies Non-
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Differentiation of early relapse and late relapse in intermediate- and high-risk neuroblastoma with anAbdominal radiology (New York) · 2024Trial
- Multimodal magnetic resonance imaging in neuroblastoma chemotherapy: a narrative review.World journal of surgical oncology · 2026Review
- Unveiling the molecular landscape: Long non-coding RNAs in neuroblastoma (Review).Oncology reports · 2026Review
- FOXR2 activation is not exclusive of CNS neuroblastoma.Neuro-oncology · 2025Article
- High resolution clonal architecture of hypomutated Wilms tumours.Nature communications · 2025Article
- Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?Genes & diseases · 2025Review
- Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities.Cancers · 2025Review
- FOXR2 Targets LHX6+/DLX+ Neural Lineages to Drive Central Nervous System Neuroblastoma.Cancer research · 2025Article
- MYCN as an oncogene in pediatric brain tumors.Frontiers in oncology · 2025Review
- FOXR2 in cancer development: emerging player and therapeutic opportunities.Oncology research · 2025Review
- Progress of targeted FOX family therapy in ovarian cancer.Frontiers in pharmacology · 2025Review
- Defining neuroblastoma: From origin to precision medicine.Neuro-oncology · 2024Review
- Identification and validation of a novel five-gene signature in high-risk MYCN-not-amplified neuroblastoma.Discover oncology · 2024Article
- Developmental origins shape the paediatric cancer genome.Nature reviews. Cancer · 2024Review
- KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA mJournal of experimental & clinical cancer research : CR · 2024Article
- Article
- A Comparative Study of Neuroendocrine Heterogeneity in Small Cell Lung Cancer and Neuroblastoma.Molecular cancer research : MCR · 2023Article
- SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma.Journal of experimental & clinical cancer research : CR · 2022Article
- GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.Journal for immunotherapy of cancer · 2022Article
- FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits.Cancer research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeClinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to fatality. Hence, understanding the mechanisms that cause tumor progression is crucial for the treatment of patients. In this study, we show that MATERIALS AND
methodsWe analyzed three independent transcriptional data sets of in total 1030 primary neuroblastomas with full clinical annotation. We performed immunoprecipitation for FOXR2 and MYCN and silenced FOXR2 expression in two neuroblastoma cell lines to examine the effect on cellular processes, transcriptome, and MYCN protein levels. Tumor samples were analyzed for protein levels of FOXR2 and MYCN.
resultsIn three combined neuroblastoma data sets, 9% of tumors show expression of
conclusionThe stabilization of MYCN by FOXR2 represents an alternative mechanism to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.